STOCK TITAN

Liminatus Pharma names Eric Sunghee Kang chief strategist

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Liminatus Pharma, Inc. appointed Eric Sunghee Kang as Chief Corporate Strategist, effective immediately on November 16, 2026. Kang will report to Chief Executive Officer Chris Kim and assist with corporate finance and capital-markets strategy, including financing transactions, and the development of new business initiatives in consultation with Kim. Kang has been Chief Executive Officer of Quantinum Investment since 2022, where he focuses on cross-border capital-markets transactions. He previously held strategy and finance, asset-management, and corporate-banking roles, and spent approximately 12 years with global financial institutions.

Filing Explained

Kang will receive no compensation for his Chief Corporate Strategist services, so the filing discloses no pay obligation for that role.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Age 43 years Eric Sunghee Kang's age stated in the appointment disclosure
Chief Executive Officer of Quantinum Investment since 2022 Kang's role at the investment firm
Prior Head of Strategy and Finance role 2025 Kang served at a Nasdaq-listed company
Prior Chief Executive Officer role 2021 Kang served at a Korean asset-management firm
Experience with global financial institutions Approximately 12 years Kang's career before his other described roles
private investments in public equity (PIPE) financial
"including private investments in public equity (PIPE)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Will LIMN's new Chief Corporate Strategist receive compensation?

He will not receive any compensation for his services as Chief Corporate Strategist.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001971387 0001971387 2026-11-16 2026-11-16 0001971387 us-gaap:CommonClassAMember 2026-11-16 2026-11-16 0001971387 us-gaap:WarrantMember 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

November 16, 2026

Date of Report (Date of earliest event reported)

 

Liminatus Pharma, Inc.
(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-42626   93-2710748
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

2251 Stern Goodman Street, Suite E, Fullerton, CA   92833
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (213) 273-5453

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   LIMN   The Nasdaq Stock Market LLC
Warrants   LIMNW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 8.01 Other Events.

 

On November 16, 2026, Liminatus Pharma, Inc. (the “Company”) appointed Eric Sunghee Kang as Chief Corporate Strategist of the Company, effective immediately. In this role, Mr. Kang will report to Chris Kim, the Company’s Chief Executive Officer, and will assist the Company with its corporate finance and capital markets strategy, including its financing transactions, and the development of new business initiatives, in consultation with the Chief Executive Officer.

 

Eric Sunghee Kang, age 43, has been the Chief Executive Officer of Quantinum Investment, an investment firm based in Seoul, Korea, since 2022, where he focuses on cross-border capital markets transactions, including private investments in public equity (PIPE) and strategic investments in Nasdaq-listed companies. Mr. Kang served as Head of Strategy and Finance of a Nasdaq-listed company in 2025, and also served as Chief Executive Officer of a Korean asset management firm in 2021. Prior to that, Mr. Kang spent approximately 12 years with global financial institutions, beginning his career as a Research Analyst in the Investment Banking Division of Morgan Stanley in Hong Kong, and subsequently serving as a Vice President in the Korean Large Corporates team of the Corporate Banking division of HSBC and as a Director of Corporate Sales in the Financial Markets division of ING Bank N.V., Seoul Branch. Mr. Kang received a Bachelor of Science in Business from the Leonard N. Stern School of Business at New York University.

 

The Company believes that Mr. Kang’s extensive experience in the U.S. and Asian capital markets and in cross-border financing transactions will be valuable to the Company as it pursues additional financing and new business initiatives to enhance stockholder value.

 

Mr. Kang will not receive any compensation for his services as Chief Corporate Strategist.

 

2

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.
  Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 18, 2026    
     
  LIMINATUS PHARMA, INC.
     
  By: /s/ Chris Kim 
  Name:  Chris Kim
  Title: Chief Executive Officer

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading